SCHEDULE 13G/A: BlackRock Discloses 4.8% Passive Stake in Larimar Therapeutics

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.8% of Larimar Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 3,079,665 shares of Larimar Therapeutics, Inc. common stock.
• This represents 4.8% of the total outstanding common stock of Larimar Therapeutics, Inc.
• The filing is an Amendment No. 1 to Schedule 13G, indicating a change from a previous filing.
• BlackRock holds sole voting power over 3,052,567 shares and sole dispositive power over 3,079,665 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The filing was made by BlackRock, Inc. as a parent holding company and control person, with several BlackRock subsidiaries identified as holding the securities.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine disclosure, but BlackRock's continued holding (or slight adjustment) indicates a stable, passive investment in Larimar Therapeutics. No negative implications are present.

Positives

• BlackRock's passive stake suggests a long-term investment perspective without intent to influence control, which can be seen as a stable investment.
• The holding is below the 5% threshold, indicating it is a passive investment and does not trigger more stringent reporting requirements (like Schedule 13D).

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Larimar Therapeutics, Inc.'s future performance or BlackRock's future investment intentions beyond the passive nature of the current holding.

Management Comments

• BlackRock, Inc. certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects a standard institutional investment disclosure by a major asset manager, BlackRock, in a biotechnology company, Larimar Therapeutics. Such passive stakes are common for large investment firms managing diversified portfolios and do not typically signal specific strategic moves within the industry, but rather a position within their managed funds.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a disclosure of a passive ownership stake by a large institutional investor. It does not provide performance metrics for direct comparison to industry peers or projects.
• The 4.8% stake is below the 5% threshold that would typically trigger a more active Schedule 13D filing, indicating a passive investment strategy consistent with many large asset managers like Vanguard, State Street, or Fidelity, who also hold diversified, passive stakes across numerous public companies.

Stakeholder Impact

• Shareholders of Larimar Therapeutics, Inc. are informed of BlackRock, Inc.'s significant, but passive, ownership stake, which may provide some stability signal from a major institutional investor.

Next Steps

• BlackRock, Inc. will continue to file amendments to Schedule 13G if there are significant changes to its beneficial ownership of Larimar Therapeutics, Inc. common stock, as required by SEC regulations.

Key Dates

Keywords

Larimar Therapeutics, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Passive Investment, SEC Filing, Biotechnology, Pharmaceuticals